DFS of 169 adult patients with AML by postconsolidation treatment group, within cytogenetic risk categories
| Cytogenetic category and group . | DFS . | |||
|---|---|---|---|---|
| Patients . | Events . | HR* . | P† . | |
| Favorable | ||||
| GO | 19 | 13 | 3.67 | 1.00 |
| Observation | 21 | 5 | 1.00 | |
| Intermediate | ||||
| GO | 53 | 33 | 1.03 | .54 |
| Observation | 52 | 31 | 1.00 | |
| Unfavorable | ||||
| GO | 3 | 2 | 4.55 | ND‡ |
| Observation | 4 | 1 | 1.00 | |
| Unknown | ||||
| GO | 10 | 7 | 1.31 | .67 |
| Observation | 7 | 4 | 1.00 | |
| Cytogenetic category and group . | DFS . | |||
|---|---|---|---|---|
| Patients . | Events . | HR* . | P† . | |
| Favorable | ||||
| GO | 19 | 13 | 3.67 | 1.00 |
| Observation | 21 | 5 | 1.00 | |
| Intermediate | ||||
| GO | 53 | 33 | 1.03 | .54 |
| Observation | 52 | 31 | 1.00 | |
| Unfavorable | ||||
| GO | 3 | 2 | 4.55 | ND‡ |
| Observation | 4 | 1 | 1.00 | |
| Unknown | ||||
| GO | 10 | 7 | 1.31 | .67 |
| Observation | 7 | 4 | 1.00 | |
HR, hazard ratio of DA+GO relative to DA.
One-sided P value for superior outcome (HR < 1) in DA+GO group, based on Cox regression likelihood ratio test.
P value not calculated because of small sample size. GO group: 2 relapses at 49 days and 15 months after postconsolidation randomization and 1 alive in CR at 42 months; observation group: 1 relapse at 19 months and 3 alive in CR at 36, 58, and 66 months.